Linked Life Data

11554216

Source:http://linkedlifedata.com/resource/pubmed/id/11554216

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2001-9-13
pubmed:abstractText
This study evaluated the efficacy and safety of three doses of topical alprostadil USP (prostaglandin E1) cream in 8 patients with Female Sexual Arousal Disorder (FSAD). Each patient was administered a single intravaginal dose of placebo followed by escalating intravaginal doses of the active drug at 2-week intervals. Alprostadil's effectiveness in enhancing subjective and physiological arousal during visual sexual stimulation was supported by patient ratings and physician assessments of vaginal erythema and transudate volume. Photoplethysmography measurement of vaginal pulse amplitude was not able to demonstrate treatment sensitivity in the present study. Adverse events included mild cases of vaginal itching and burning. The data support further investigation of the use of alprostadil for FSAD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0092-623X
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
531-40
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
Topical alprostadil in the treatment of Female Sexual Arousal Disorder: a pilot study.
pubmed:affiliation
Target Health Inc., 305 Madison Avenue, 25th Floor, New York, NY 10165, USA. aislam@TargetHealth.com
pubmed:publicationType
Journal Article, Clinical Trial